Etretinate

Summary

Etretinate (CHEMBL464) is an approved small-molecule keratolytic drug (ATC D05BB01); indicated across 1 condition including psoriasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D05BB01
• Indications: 1 condition
• Chemistry: 354.5 Da · C23H30O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL464
Name	Etretinate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5282375
ChEBI	CHEBI:4913
ATC	D05BB01
Molecular formula	C23H30O3
Molecular weight	354.5
InChIKey	HQMNCQVAMBCHCO-DJRRULDNSA-N

SMILES: CCOC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C

IUPAC name: ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate

Pharmacological roles (ChEBI): keratolytic drug.

Also known as: Acitretin related compound b, Ethyl etrinoate, Etretinate, Etretinato, NSC-297936, RO-109359, Tegison, Tigason, etretinate, ETRETINATE, SID50112753, SID144206054

Patent coverage: 2,172 distinct patent families (8,299 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,298 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psoriasis	4	MONDO:0005083	EFO:0000676

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).